Observational analysis shows response rates for gedatolisib, palbociclib, and letrozole in patients with advanced HER2-negative cancer, suggesting effective treatment options.
Response rates to gedatolisib + palbociclib + letrozole in the response evaluable set.
No takes yet. Share an insight, caveat, or question.
Wesolowski et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: